Abstract:Introduction: Infections are a leading cause of mortality in patients with systemic lupus erythematosus (SLE). Among various infections, invasive fungal infections (IFIs) have a particularly high mortality rate; however, studies examining IFIs in patients with SLE are limited. Methods: Patients diagnosed as having SLE between 1997 and 2012 were enrolled from Taiwan's National Health Insurance Research Database along with age- and sex-matched non-SLE controls at a ratio of 1:10. IFIs were identified based on International Classification of Diseases, Ninth Revision, Clinical Modification codes and validated by the prescriptions of systemic antifungal agents. The incidence rate (IR), incidence rate ratio (IRR), and all-cause mortality rate of IFIs and its subtypes were analyzed. A Cox multivariate regression model with time-dependent covariates was applied to analyze independent risk factors for IFIs. Results: A total of 24,541 patients with SLE and 245,410 non-SLE controls were included. We observed 445 IFI episodes in the SLE cohort, with an all-cause mortality rate of 26.7%. Candida spp. (52.8%) was the most common pathogen, followed by Cryptococcus spp. (18.2%) and Aspergillus spp. (18.2%). The IR of IFIs in the SLE cohort was 20.83 per 10,000 person-years, with an IRR of 11.1 [95% confidence interval (CI): 9.8-12.6] relative to the non-SLE controls. Juvenile patients with SLE aged ⩽18 years had the highest IRR of 47.2 (95% CI: 26.9-86.8). Intravenous steroid therapy administered within 60 days (hazard ratio: 29.11, 95% CI: 23.30-36.37) was the most critical risk factor for overall IFIs and each of the three major fungal pathogens. Distinct risk factors were found among different IFI subtypes. Conclusion: Patients with SLE had a higher risk of IFIs, especially juvenile patients. Intravenous steroid therapy is the most critical risk factor for IFIs. This study provides crucial information for the risk stratification of IFIs in SLE. Plain language summaries: Patients with systemic lupus erythematosus and physicians treating this patient group should be aware of the risk of invasive fungal infections.Invasive fungal infections (IFIs) are a severe complication with a high mortality rate among patients with systemic lupus erythematosus (SLE); however, studies on this topic are scant. We performed a nationwide population-based study in Taiwan to estimate the incidence and mortality of and risk factors for IFIs. We found an incidence rate of 20.83 per 10,000 person-years for IFIs, with a mortality rate of 26.7%. Juvenile patients aged ⩽18 years had the highest relative risk of IFIs. Although candidiasis was the most common IFI, cryptococcosis and aspergillosis should be concerned in juvenile patients as well. Intravenous steroid therapy was the most critical risk factor for all IFIs, and different immunosuppressive agents posed different risks in patients for acquiring certain fungal pathogens.Our findings provide pivotal epidemiological information and indicate risk factors for IFIs in patients with SLE. Age and exposure to specific immunosuppressants and steroids might help predict the risk of IFIs. Because the manifestation of these infections is sometimes indistinguishable from a lupus flare, physicians should be aware of this fatal complication, especially when patients are not responsive to immunosuppressive therapy. Early recognition, implication of diagnostic tools, and empirical antimicrobial agents can be the key to treating patients with IFIs. Additional studies are required to develop a risk management program for patients with SLE.

Dilemma of Immunosuppression and Infection Risk in Systemic Lupus Erythematosus

Comparison of Short Interval and Low Dose (SILD) with High Dose of Cyclophosphamide in the Susceptibility to Infection in SLE: a Multicentrereal-World Study

Immunological pathogenesis and treatment of systemic lupus erythematosus

Risk Factors for Serious Infections in Inpatients with Systemic Lupus Erythematosus.

Systemic lupus erythematosus and infections

The State of Infection and Treatment Decisions of Systemic Lupus Erythematosus

Current mechanistic insights into the role of infection in systemic lupus erythematosus

Risk factors for initial and recurrent severe infections in first hospitalized patients with systemic lupus erythematosus: A retrospective study of a Chinese cohort

A clinical retrospective study of 130 systemic lupus erythematosus patients complicated with infections

T Cell Subsets and Immunoglobulin G Levels Are Associated with the Infection Status of Systemic Lupus Erythematosus Patients

Infection Profile and Risk Factors for Mortality in Patients with End-Stage Renal Disease Attributable to Systemic Lupus Erythematosus: a Two-Center Integrated Study

Analysis on the Risk Factors of Infection in Late-onset Systemic Lupus Erythematosus Patients

THU0036 Discriminating Central Nervous System Infection and Neuropsychiatric Involvement in Patients with Systemic Lupus Erythematosus: A Single-Center Experience

Immune profile alterations of systemic lupus erythematosus patients with infections

Major infections in newly diagnosed systemic lupus erythematosus: an inception cohort study

Meta-analysis of Clinical Risk Factors of Patients with Systemic Lupus Erythematosus Complicated with Invasive Fungal Infection

Neutralizing anti-IFN-γ IgG was increased in patients with systemic lupus erythematosus and associated with susceptibility to infection

Epidemiology and risk of invasive fungal infections in systemic lupus erythematosus: a nationwide population-based cohort study

Low-dose IL-2 Therapy Invigorates CD8+ T Cells for Viral Control in Systemic Lupus Erythematosus

Major Infections of Newly Diagnosed Childhood-Onset Systemic Lupus Erythematosus

Update on infections and vaccinations in systemic lupus erythematosus and Sjögren's syndrome